Reduced monocyte CD86 expression in postinflammatory immunodeficiency
- 1 February 2007
- journal article
- research article
- Published by Wolters Kluwer Health in Critical Care Medicine
- Vol. 35 (2) , 458-467
- https://doi.org/10.1097/01.ccm.0000254724.54515.2f
Abstract
Major surgery, polytrauma, stroke, and pancreatitis frequently lead to a compensatory anti-inflammatory response syndrome that often predisposes patients to lethal infections. This temporary postinflammatory immunodeficiency is characterized by altered function of blood monocytes. These cells show strongly reduced inflammatory and antigen-presentation capacity. Diminished monocyte expression of the major histocompatibility complex class II molecule human leukocyte antigen (HLA)-DR is a well-established diagnostic marker of this immunodeficiency. To further characterize the monocytic cells in this clinical state, we analyzed their expression of CD86, the most important co-stimulatory molecule. Analysis of blood samples that entered the clinical immunologic diagnostics and of cells from an in vitro model of postinflammatory immunodeficiency. University laboratory. Healthy donors and intensive care unit (ICU) patients at the university hospital. None. The expression of HLA-DR on monocytes and of CD86 and CD80 on monocytes and B cells was analyzed by flow cytometry. Messenger RNA expression of CD86 was analyzed in isolated monocytes by real-time polymerase chain reaction on reverse transcribed. The normal range of monocyte CD86 expression in healthy subjects was established to be from 2128 to 5102 surface molecules per cell and was independent of age, gender, and leukocyte and monocyte count. The CD86 expression on monocytes in ICU patients correlated with HLA-DR expression. Approximately 40% of the ICU patients with long-term reduced monocyte HLA-DR expression had a long-term reduction of CD86 expression. Patients in whom the expression of both molecules was diminished had an unfavorable prognosis. The diminished number of CD86 surface molecules on monocytes was associated with reduced CD86 messenger RNA levels in these cells. The expression of CD86 in B cells was not diminished in immunodeficient patients. The expression of CD80 in both monocytes and B-cells was minimal in healthy donors and not clearly changed in patients. The monocyte CD86 expression may be a helpful diagnostic variable in ICU patients.Keywords
This publication has 51 references indexed in Scilit:
- The expression of legumain, an asparaginyl endopeptidase that controls antigen processing, is reduced in endotoxin-tolerant monocytesGenes & Immunity, 2005
- Is there an interaction between interleukin-10 and interleukin-22?Genes & Immunity, 2004
- What's the difference between CD80 and CD86?Trends in Immunology, 2003
- The Pathophysiology and Treatment of SepsisNew England Journal of Medicine, 2003
- NF-κB regulation in the immune systemNature Reviews Immunology, 2002
- The B7–CD28 superfamilyNature Reviews Immunology, 2002
- Pro‐ versus Anti‐inflammatory Cytokine Profile in Patients with Severe Sepsis: A Marker for Prognosis and Future Therapeutic OptionsThe Journal of Infectious Diseases, 2000
- CD28 and CTLA-4 have opposing effects on the response of T cells to stimulation.The Journal of Experimental Medicine, 1995
- Dendritic cell loss from nonlymphoid tissues after systemic administration of lipopolysaccharide, tumor necrosis factor, and interleukin 1.The Journal of Experimental Medicine, 1995
- Mechanism of endotoxin desensitization: involvement of interleukin 10 and transforming growth factor beta.The Journal of Experimental Medicine, 1995